Arrowhead Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 8 trials

Phase 2 14 trials

TrialDrugs studiedStatusPrimary completion
Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaNCT07241546ARO-RAGERecruiting2027-12Estimated
Study of ARO-APOC3 in Adults With DyslipidemiaNCT05413135ARO-APOC3Completed2025-09-22Actual
Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaNCT04720534ARO-APOC3Completed2023-03-09Actual
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaNCT04998201ARO-APOC3Completed2023-02-10Actual
Study of ARO-ANG3 in Adults With Mixed DyslipidemiaNCT04832971ARO-ANG3Completed2022-08-30Actual
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)NCT03946449ARO-AATCompleted2022-04-28Actual
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)NCT03945292Fazisiran InjectionCompleted2021-11-08Actual
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)NCT05217667ARO-ANG 3 InjectionTerminated2023-05-02Actual
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionNCT02065336ARC-520, chlorpheniramine, entecavirTerminated2017-01Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionNCT02604199ARC-520 Injection, antihistamine, entecavir, tenofovirTerminated2017-01Actual
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528ARC-520, Entecavir, Tenofovir, diphenhydramineTerminated2016-12Actual
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029ARC-520, antihistamine, entecavir, pegylated interferon alpha 2a and 1 moreTerminated2016-12Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212ARC-520, antihistamine, entecavir, tenofovirTerminated2016-12Actual
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionNCT02738008ARC-520 Injection, antihistamine, entecavir, tenofovirTerminated2016-12Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Study of ARO-APOC3 in Adults With Dyslipidemia

NCT05413135 · Arrowhead Pharmaceuticals

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time frame: Through 24 months. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Description: An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs that started on or after the first dose date of study drug. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. Time frame: Baseline through Month 24.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 869 participants (planned). After: 710 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 70 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24. After: Measure: Percent Change From Baseline in Fasting LDL-C at Week 24.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting TG.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10. After: Measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG).

Check registry source
Study of ARO-APOC3 in Adults With Dyslipidemia

NCT05413135 · Arrowhead Pharmaceuticals

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 18 Sep 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source